argenx (NASDAQ:ARGX) Given New $720.00 Price Target at HC Wainwright

argenx (NASDAQ:ARGX) had its price target lifted by stock analysts at HC Wainwright from $717.00 to $720.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 15.26% from the company’s previous close.

Several other equities analysts have also weighed in on ARGX. Guggenheim boosted their target price on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a report on Friday, November 1st. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. increased their price objective on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. JMP Securities lifted their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $658.56.

argenx Stock Performance

NASDAQ:ARGX opened at $624.70 on Friday. argenx has a one year low of $349.86 and a one year high of $678.21. The stock has a market cap of $37.96 billion, a PE ratio of -709.89 and a beta of 0.58. The stock has a 50 day moving average price of $642.61 and a 200 day moving average price of $589.72.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, analysts predict that argenx will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenx

Large investors have recently modified their holdings of the stock. US Bancorp DE grew its stake in argenx by 7.8% during the 3rd quarter. US Bancorp DE now owns 4,350 shares of the company’s stock worth $2,358,000 after purchasing an additional 316 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in shares of argenx by 201.2% during the third quarter. Janney Montgomery Scott LLC now owns 2,072 shares of the company’s stock worth $1,123,000 after buying an additional 1,384 shares during the period. Nvwm LLC purchased a new stake in shares of argenx during the third quarter worth approximately $533,000. Keudell Morrison Wealth Management acquired a new stake in argenx in the third quarter valued at approximately $207,000. Finally, Assetmark Inc. lifted its stake in argenx by 8.3% in the third quarter. Assetmark Inc. now owns 7,769 shares of the company’s stock worth $4,211,000 after acquiring an additional 598 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.